Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

Quickstart highlights

Vesugen (Lys-Glu-Asp, KED tripeptide — same as Crystagen sequence, may vary by formulation) is a vascular-targeting bioregulator from Khavinson's group.

  • Concentration: 2 mg/mL (20 mg + 10 mL bac water).
  • At 2 mg/mL: 200 µg = 10 units daily x 10 days.
  • Vesugen targets endothelial eNOS, ICAM-1/VCAM-1, and vascular smooth muscle gene normalization.
  • Combine with Cardiogen for comprehensive cardiac + vascular anti-aging.
  • Monitor BP before, during, and after each course to track vascular response.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-2 (10-day course)20010Once daily (morning)200 µg — 10 units; standard 10-day course; 20 mg vial = 100 doses
Maintenance20010Every other day200 µg EOD — vascular maintenance

Reconstitution steps

  1. Reconstitute in 2.5 mL bac water portions; inject slowly down vial wall.
  2. Swirl gently until dissolved. Final concentration: 2 mg/mL.
  3. Label with date; refrigerate 2–8 °C. Use within 28 days.

Supplies needed

10_day-week plan

  • 1 vial
  • 10 syringes
  • 2 mL bac water
  • 10 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Normalize vascular endothelial cell gene expression for eNOS production, anti-inflammatory signaling, and arterial compliance through the Vesugen tetrapeptide vascular bioregulator 10-day intensive course.

Off-cycle: 4–6 months between courses.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted: refrigerate 2–8 °C; use within 28 days.

Injection & tracking tips

  • Morning injection — vascular bioregulators support daytime endothelial function when blood pressure and flow demands are highest.
  • Vesugen may be combined with Cardiogen for comprehensive cardiovascular anti-aging support.
  • Monitor blood pressure before each course to track vascular response.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Blood pressure (systolic/diastolic) twice weekly throughout the protocol.
  • Endothelial function assessment (brachial artery flow-mediated dilation) at baseline and 3 months if available.
  • Track morning pulse pressure and resting heart rate weekly.
Log your cycle in the calculator →

How this works & references

Vesugen (Lys-Glu-Asp, KED tripeptide — same as Crystagen sequence, may vary by formulation) is a vascular-targeting bioregulator from Khavinson's group. Proposed mechanisms: normalization of endothelial nitric oxide synthase (eNOS) gene expression, improving vascular tone and blood flow; restoration of ICAM-1 and VCAM-1 (adhesion molecule) expression normalization, reducing inflammatory cell recruitment to vessel walls; improvement of arterial wall smooth muscle gene expression for compliance. Applied in Russian clinical settings for essential hypertension support, arteriosclerosis prevention, and age-related vascular decline.

Sources

  • Source: Khavinson VK et al. — Vascular bioregulators and endothelial function. Ann N Y Acad Sci. 2010

Frequently asked questions

Can Vesugen lower blood pressure?
Vesugen's proposed eNOS normalization would increase nitric oxide production in endothelial cells, which dilates blood vessels and reduces blood pressure. Russian clinical experience reports modest antihypertensive effects (5–10 mmHg systolic reduction) in hypertensive patients during Vesugen courses. These are not a replacement for pharmaceutical antihypertensives but may provide adjunct support.
How does Vesugen protect against arteriosclerosis?
Arteriosclerosis involves endothelial dysfunction (reduced eNOS, increased adhesion molecules), smooth muscle proliferation, and inflammatory cell infiltration. Vesugen's gene normalization of eNOS, ICAM-1, and smooth muscle genes theoretically addresses all three components. The effect is preventive (slowing progression) rather than reversive for established calcified plaque.
Can Vesugen be combined with Cardiogen?
Yes — this is a natural combination: Cardiogen for cardiomyocyte protection and contractile gene normalization; Vesugen for vascular endothelial health and arterial compliance. Russian anti-aging clinics often sequence 10-day courses of different bioregulators throughout the year to cover multiple organ systems.
Is there any interaction between Vesugen and antihypertensive medications?
No pharmacokinetic interactions are expected — Vesugen is a gene expression modulator, not a direct vasodilator or pharmacological receptor ligand. If Vesugen produces meaningful blood pressure reduction (via eNOS normalization), patients on antihypertensives should monitor BP more frequently during courses and discuss medication dose adjustment with their physician if BP drops below target.
Who should prioritize Vesugen in an anti-aging bioregulator protocol?
Individuals with: (1) Elevated cardiovascular risk (hypertension, metabolic syndrome, smoking history); (2) Age-related arterial stiffness (elevated pulse pressure, widened pulse wave velocity); (3) Endothelial dysfunction markers (reduced flow-mediated dilation, elevated hsCRP); (4) Family history of premature cardiovascular disease. Vesugen is appropriate as a preventive vascular aging intervention.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.